Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
03 10 2019
Historique:
received: 07 06 2019
accepted: 04 09 2019
entrez: 4 10 2019
pubmed: 4 10 2019
medline: 21 10 2020
Statut: epublish

Résumé

BACKGROUNDFecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridioides difficile infection (rCDI) in adults and children, but donor stool samples are currently screened for only a limited number of potential pathogens. We sought to determine whether putative procarcinogenic bacteria (enterotoxigenic Bacteroides fragilis, Fusobacterium nucleatum, and Escherichia coli harboring the colibactin toxin) could be durably transmitted from donors to patients during FMT.METHODSStool samples were collected from 11 pediatric rCDI patients and their respective FMT donors prior to FMT as well as from the patients at 2-10 weeks, 10-20 weeks, and 6 months after FMT. Bacterial virulence factors in stool DNA extracts and stool cultures were measured by quantitative PCR: Bacteroides fragilis toxin (bft), Fusobacterium adhesin A (fadA), and Escherichia coli colibactin (clbB).RESULTSFour of 11 patients demonstrated sustained acquisition of a procarcinogenic bacteria. Whole genome sequencing was performed on colony isolates from one of these donor/recipient pairs and demonstrated that clbB+ E. coli strains present in the recipient after FMT were identical to a strain present in the donor, confirming strain transmission. Conversely, 2 patients exhibited clearance of procarcinogenic bacteria following FMT from a negative donor.CONCLUSIONBoth durable transmission and clearance of procarcinogenic bacteria occurred following FMT, suggesting that additional studies on appropriate screening measures for FMT donors and the long-term consequences and/or benefits of FMT are warranted.FUNDINGCrohn's & Colitis Foundation, the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, the National Cancer Institute, and the Canadian Institutes of Health Research.

Identifiants

pubmed: 31578306
pii: 130848
doi: 10.1172/jci.insight.130848
pmc: PMC6795395
doi:
pii:

Substances chimiques

DNA, Bacterial 0
RNA, Ribosomal, 16S 0
Virulence Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : K99 CA230192
Pays : United States
Organisme : NICHD NIH HHS
ID : T32 HD044355
Pays : United States
Organisme : CIHR
Pays : Canada

Références

J Pediatr Gastroenterol Nutr. 2014 May;58(5):588-92
pubmed: 24792627
Anaerobe. 2016 Aug;40:50-3
pubmed: 27166180
Anaerobe. 2006 Feb;12(1):17-22
pubmed: 16701608
Aliment Pharmacol Ther. 2016 Feb;43(4):445-57
pubmed: 26662643
Clin Microbiol Infect. 2019 Jul;25(7):830-838
pubmed: 30616014
J Infect Dis. 2018 Jan 30;217(4):628-636
pubmed: 29186529
J Clin Microbiol. 1998 Jun;36(6):1729-32
pubmed: 9620408
Cell Host Microbe. 2013 Aug 14;14(2):195-206
pubmed: 23954158
Clin Infect Dis. 2015 Jan 15;60(2):208-15
pubmed: 25305284
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376186
Nat Med. 2019 Apr;25(4):679-689
pubmed: 30936547
Acta Gastroenterol Belg. 2006 Jan-Mar;69(1):25-30
pubmed: 16673559
NPJ Biofilms Microbiomes. 2017 Nov 29;3:34
pubmed: 29214046
Genome Res. 2012 Feb;22(2):299-306
pubmed: 22009989
Aliment Pharmacol Ther. 2015 Sep;42(6):741-52
pubmed: 26198180
Science. 2016 Apr 29;352(6285):586-9
pubmed: 27126044
Infect Immun. 2011 May;79(5):2012-20
pubmed: 21402766
Front Microbiol. 2018 Nov 02;9:2622
pubmed: 30450088
Microbiome. 2013 Jan 09;1(1):3
pubmed: 24467987
PeerJ. 2018 May 30;6:e4663
pubmed: 29868248
Genome Res. 2016 Dec;26(12):1721-1729
pubmed: 27852649
Clin Infect Dis. 2016 Mar 1;62(5):596-602
pubmed: 26565008
Dig Dis Sci. 2014 Sep;59(9):2222-7
pubmed: 24788321
Anaerobe. 2011 Apr;17(2):64-8
pubmed: 21439390
PLoS One. 2014 Jan 09;9(1):e85280
pubmed: 24416378
Clin Microbiol Infect. 2014 Nov;20(11):O977-8
pubmed: 24845223
J Diarrhoeal Dis Res. 1992 Mar;10(1):4-9
pubmed: 1619243
Scand J Infect Dis. 1995;27(3):211-5
pubmed: 8539543
Genome Biol. 2014;15(11):524
pubmed: 25410596
Nat Med. 2018 Dec;24(12):1804-1808
pubmed: 30420754
Clin Infect Dis. 2018 Mar 19;66(7):987-994
pubmed: 29562266
J Clin Microbiol. 2000 May;38(5):1996-7
pubmed: 10790139
J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):23-6
pubmed: 25162365
J Clin Microbiol. 1997 Oct;35(10):2482-6
pubmed: 9316893
J Pediatr Gastroenterol Nutr. 2014 Nov;59(5):565-70
pubmed: 25023578
Am J Gastroenterol. 2014 Jul;109(7):1065-71
pubmed: 24890442
Clin Microbiol Rev. 2009 Apr;22(2):349-69, Table of Contents
pubmed: 19366918
J Hosp Infect. 2018 Aug;99(4):481-486
pubmed: 29477634
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Am J Gastroenterol. 2012 Dec;107(12):1930-1
pubmed: 23211865
J Infect Dis. 2016 Jul 15;214(2):173-81
pubmed: 26908752
J Bacteriol. 2005 Aug;187(15):5330-40
pubmed: 16030227
Pediatr Infect Dis J. 2014 Nov;33(11):1198-200
pubmed: 24853539
FEMS Microbiol Lett. 2000 Jan 1;182(1):171-6
pubmed: 10612750
Aliment Pharmacol Ther. 2015 May;41(9):835-43
pubmed: 25728808
Cell Host Microbe. 2013 Aug 14;14(2):207-15
pubmed: 23954159
Inflamm Bowel Dis. 2011 Sep;17(9):1971-8
pubmed: 21830275
Gut. 2018 May;67(5):882-891
pubmed: 28341746
Infect Immun. 2009 Nov;77(11):4696-703
pubmed: 19720753
Clin Microbiol Infect. 2006 Aug;12(8):782-6
pubmed: 16842574
Gastroenterology. 2015 Jul;149(1):102-109.e6
pubmed: 25857665
Anaerobe. 2013 Feb;19:22-6
pubmed: 23182843
Cell Host Microbe. 2014 Mar 12;15(3):317-28
pubmed: 24629338
Int J Pharm. 2017 Dec 20;534(1-2):25-34
pubmed: 28986322
Cell Host Microbe. 2018 Feb 14;23(2):229-240.e5
pubmed: 29447696
JAMA. 2019 Jan 15;321(2):156-164
pubmed: 30644982
Clin Microbiol Infect. 2018 Apr;24(4):350-354
pubmed: 29309930
Science. 2012 Oct 5;338(6103):120-3
pubmed: 22903521
Nat Med. 2009 Sep;15(9):1016-22
pubmed: 19701202
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
Lancet. 2017 Mar 25;389(10075):1218-1228
pubmed: 28214091

Auteurs

Julia L Drewes (JL)

Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Alina Corona (A)

Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Uriel Sanchez (U)

Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Yunfan Fan (Y)

Department of Biomedical Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, Maryland, USA.

Suchitra K Hourigan (SK)

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Melissa Weidner (M)

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Sarah D Sidhu (SD)

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Patricia J Simner (PJ)

Division of Medical Microbiology, Department of Pathology.

Hao Wang (H)

Department of Oncology, Bioinformatics and Biostatistics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Winston Timp (W)

Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Biomedical Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, Maryland, USA.

Maria Oliva-Hemker (M)

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Cynthia L Sears (CL)

Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Bloomberg-Kimmel Institute for Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH